SXTP

60 Degrees Pharmaceuticals Inc. (SXTP) | Rumor.io

60 Degrees Pharmaceuticals

SXTP

Attention (50-day avg)0%

Attention rank (50-day avg)#2,685

Bullish sentiment (50-day avg)100%

Price to earnings ratio14.7

Market capitalization4.4M

Earnings per share-2.67

Dividend yield (TTM)—

Revenue (annual)1M

Net income (annual)-7.4M

Social

What share of all stock conversation is about SXTP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 28

60 Degrees Pharmaceuticals, Inc. (SXTP) has an FDA-approved drug undergoing testing, with some anticipating significant price increases ($3.00, $4.50, $6.00).
Knight therapeutics is trading at $1.50, aiming to break even on their swing trade, with some speculating that the company may take in 2x, 3x, or 4x their investment.
Accumulation on 60 Degrees Pharmaceuticals, Inc. has occurred on tiny volume, and some believe the stock will surge in price once it appears on volume scanners.

Generated by AI

Sentiment

Of the messages about SXTP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% 0	83.55% -0.89
Bearish	0%	0% 0	0% 0	16.45% +0.89

Bullish· Mar 12

The company's tafenoquine treatment has shown a 100% cure rate in babesiosis patients, supporting a potential guideline review and expanded use.
The stock has broken through a key resistance level at $239.19, with a high volume of 57.29M confirming the breakout and setting a technical target at $538.81.
The company's clinical trial success and strong internal confidence, amplified by positive clinical trial data, have driven a surge in the stock price, up 71.28% to $3.22.

Bearish· Mar 11

The company has a cure for a major killer, which may lead to a price drop as investors sell their shares.
Hedge funds are heavily shorting the asset, increasing the likelihood of a price drop.
The asset has experienced a significant pullback, with support at $2.14 and potential exit at $2.4.

Generated by AI

Topics

Of the messages about SXTP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	75%	91.67%	45.98%
Technical Analysis	100%	25%	8.33%	24.37%
Analysts	0%	0%	0%	9.88%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	19.77%

Announcements· Mar 12

60 Degrees Pharmaceuticals, Inc. announces that all patients in the expanded-access study achieved cure for babesiosis with tafenoquine, supporting a potential guideline review and expanded use.
The company's tafenoquine treatment has demonstrated strong clinical execution and validated its cash flow potential in a high-growth niche, with a 100% cure rate in babesiosis patients.
A management buyback signals strong internal confidence, amplified by positive clinical trial data, and a significant dark pool accumulation is observed, following a major clinical catalyst.

Technical Analysis· Jan 22

$SXTP is holding above 7.60-80 and needs to maintain this level to continue its upward trend.
Historically, $SXTP has faded well after making a >100% move from the previous day's close to PMH, and this pattern may repeat in current market conditions.
$SXTP has formed a falling wedge pattern, which could be a sign of a potential breakout, and is also showing strong volume confirmation of its upward trend.

Generated by AI

Community

Of the messages about SXTP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	81.25%	83.87%	17.76%
Newcomers	0%	18.75%	16.13%	82.24%

Regulars· Sep 28

Knight Therapeutics' swing trade on SXTP aims to break even at $1.50, with potential for 2x, 3x, or 4x returns.
Accumulation in SXTP has occurred on low volume, and the stock may surge once volume scanners pick up on it.
The low float in SXTP may lead to a rapid price increase, with some participants positioned for entry at higher prices.

Newcomers· Mar 12

The stock price of 60 Degrees Pharmaceuticals, Inc. (SXTP) surged to $3.22, up 71.28%, on positive clinical trial data showing a 100% cure rate for babesiosis with tafenoquine.
The company's 100% cure rate for babesiosis with tafenoquine is a significant medical breakthrough, but some market observers warn that "the better the news, the sharper the trap" and that retail investors may be trapped by the news.
The stock's profit growth has accelerated rapidly, with a 45x float rotation and over 12x rvol, making it a top watch for continuation tomorrow via a simple S/D flip setup.

Generated by AI

– On-demand company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET – – Management will be available for one-on-one investor meetings during the conference – WASHINGTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced that management will participate in the H.C. Wainwright 28th Annual

27d agoYahoo Finance

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

Detailed price information for 60 Degrees Pharmaceuticals Inc (SXTP-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand

1mo agoYahoo Finance

60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions

Detailed price information for 60 Degrees Pharmaceuticals Inc (SXTP-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

60 Degrees Pharmaceuticals raises $1M in private placement

2mo agoInvesting.com

Also Discussed

Investors talking about SXTP also mention

#	Name	Attention
1	Brand Engagement Network Inc.BNAI	0%+0
2	WRNT - Warrantee Inc. American Depositary Shares	——
3	Agape Atp CorpATPC	0%0
4	Banzai International Inc.BNZI	0%new
5	Azitra Inc.AZTR	0%0
6	Autonomix Medical Inc.AMIX	0%0
7	MKDWELL Tech Inc.MKDW	0%+0
8	Lavoro LimitedLVRO	0%new
9	BioNexus Gene Lab Corp.BGLC	0%0
10	CytoMed Therapeutics Ltd.GDTC	0%0

60 Degrees Pharmaceuticals Inc.

Healthcare
Biotechnology

60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections. The company works across areas such as malaria, babesiosis, respiratory infections, and dengue, reflecting a research strategy aimed at diseases with significant unmet medical need. 60 Degrees Pharmaceuticals Inc. serves as a niche biotechnology player in the healthcare market, combining product commercialization with ongoing clinical development. Headquartered in Washington, D.C., the company also maintains operations linked to research and collaboration in Australia.

Website

Location

1025 Connecticut Avenue NW

Washington, DC, 20036

United States

Social

What share of all stock conversation is about SXTP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 28

60 Degrees Pharmaceuticals, Inc. (SXTP) has an FDA-approved drug undergoing testing, with some anticipating significant price increases ($3.00, $4.50, $6.00).
Knight therapeutics is trading at $1.50, aiming to break even on their swing trade, with some speculating that the company may take in 2x, 3x, or 4x their investment.
Accumulation on 60 Degrees Pharmaceuticals, Inc. has occurred on tiny volume, and some believe the stock will surge in price once it appears on volume scanners.

Generated by AI

Sentiment

Of the messages about SXTP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	100% 0	83.55% -0.89
Bearish	0%	0% 0	0% 0	16.45% +0.89

Bullish· Mar 12

The company's tafenoquine treatment has shown a 100% cure rate in babesiosis patients, supporting a potential guideline review and expanded use.
The stock has broken through a key resistance level at $239.19, with a high volume of 57.29M confirming the breakout and setting a technical target at $538.81.
The company's clinical trial success and strong internal confidence, amplified by positive clinical trial data, have driven a surge in the stock price, up 71.28% to $3.22.

Bearish· Mar 11

The company has a cure for a major killer, which may lead to a price drop as investors sell their shares.
Hedge funds are heavily shorting the asset, increasing the likelihood of a price drop.
The asset has experienced a significant pullback, with support at $2.14 and potential exit at $2.4.

Generated by AI

Topics

Of the messages about SXTP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	75%	91.67%	45.98%
Technical Analysis	100%	25%	8.33%	24.37%
Analysts	0%	0%	0%	9.88%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	19.77%

Announcements· Mar 12

60 Degrees Pharmaceuticals, Inc. announces that all patients in the expanded-access study achieved cure for babesiosis with tafenoquine, supporting a potential guideline review and expanded use.
The company's tafenoquine treatment has demonstrated strong clinical execution and validated its cash flow potential in a high-growth niche, with a 100% cure rate in babesiosis patients.
A management buyback signals strong internal confidence, amplified by positive clinical trial data, and a significant dark pool accumulation is observed, following a major clinical catalyst.

Technical Analysis· Jan 22

$SXTP is holding above 7.60-80 and needs to maintain this level to continue its upward trend.
Historically, $SXTP has faded well after making a >100% move from the previous day's close to PMH, and this pattern may repeat in current market conditions.
$SXTP has formed a falling wedge pattern, which could be a sign of a potential breakout, and is also showing strong volume confirmation of its upward trend.

Generated by AI

Community

Of the messages about SXTP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	81.25%	83.87%	17.76%
Newcomers	0%	18.75%	16.13%	82.24%

Regulars· Sep 28

Knight Therapeutics' swing trade on SXTP aims to break even at $1.50, with potential for 2x, 3x, or 4x returns.
Accumulation in SXTP has occurred on low volume, and the stock may surge once volume scanners pick up on it.
The low float in SXTP may lead to a rapid price increase, with some participants positioned for entry at higher prices.

Newcomers· Mar 12

The stock price of 60 Degrees Pharmaceuticals, Inc. (SXTP) surged to $3.22, up 71.28%, on positive clinical trial data showing a 100% cure rate for babesiosis with tafenoquine.
The company's 100% cure rate for babesiosis with tafenoquine is a significant medical breakthrough, but some market observers warn that "the better the news, the sharper the trap" and that retail investors may be trapped by the news.
The stock's profit growth has accelerated rapidly, with a 45x float rotation and over 12x rvol, making it a top watch for continuation tomorrow via a simple S/D flip setup.

Generated by AI

60 Degrees Pharmaceuticals

Social

Sep 28

Bullish· Mar 12

Bearish· Mar 11

Announcements· Mar 12

Technical Analysis· Jan 22

Regulars· Sep 28

Newcomers· Mar 12

60 Degrees Pharmaceuticals at H.C. Wainwright: babesiosis push in focus

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions

60 Degrees Pharmaceuticals raises $1M in private placement

Also Discussed

60 Degrees Pharmaceuticals Inc.

Company Information

Location

60 Degrees Pharmaceuticals at H.C. Wainwright: babesiosis push in focus

60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions

60 Degrees Pharmaceuticals raises $1M in private placement

Also Discussed

Social

Sep 28

Bullish· Mar 12

Bearish· Mar 11

Announcements· Mar 12

Technical Analysis· Jan 22

Regulars· Sep 28

Newcomers· Mar 12